Literature DB >> 28983790

Influenza Vaccination in Patients with Common Variable Immunodeficiency (CVID).

Jan F Mieves1, Kirsten Wittke1, Helma Freitag1, Hans-Dieter Volk1,2, Carmen Scheibenbogen1, Leif G Hanitsch3.   

Abstract

PURPOSE OF REVIEW: Vaccination against influenza in patients with primary antibody deficiency is recommended. Common variable immunodeficiency (CVID) is the most frequent and clinically relevant antibody deficiency disease and is by definition characterized by an impaired vaccination response. The purpose of this review is to present the current knowledge of humoral and cellular vaccine response to influenza in CVID patients. RECENT
FINDINGS: Studies conducted in CVID patients demonstrated an impaired humoral response upon influenza vaccination. Data on cellular immune response are in part conflicting, with two out of three studies showing responses similar to healthy controls. Available data suggest a benefit from influenza vaccination in CVID patients. Therefore, annual influenza vaccination in patients and their close household contacts is recommended.

Entities:  

Keywords:  Common variable immunodeficiency; Influenza; Primary antibody deficiency; Vaccination

Mesh:

Substances:

Year:  2017        PMID: 28983790     DOI: 10.1007/s11882-017-0749-3

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  66 in total

1.  Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children.

Authors:  Steven Black; Uwe Nicolay; Timo Vesikari; Markus Knuf; Giuseppe Del Giudice; Giovanni Della Cioppa; Theodore Tsai; Ralf Clemens; Rino Rappuoli
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

2.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

3.  Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age.

Authors:  Joan Puig-Barberà; Javier Diez-Domingo; Santiago Pérez Hoyos; Angel Belenguer Varea; David González Vidal
Journal:  Vaccine       Date:  2004-12-02       Impact factor: 3.641

Review 4.  Urgent challenges in implementing live attenuated influenza vaccine.

Authors:  Anika Singanayagam; Maria Zambon; Ajit Lalvani; Wendy Barclay
Journal:  Lancet Infect Dis       Date:  2017-08-02       Impact factor: 25.071

5.  Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine.

Authors:  Claire-Anne Siegrist; Juan Ambrosioni; Michael Bel; Christophe Combescure; Karine Hadaya; Pierre-Yves Martin; Paola M Soccal; Thierry Berney; Stephane Noble; Sara Meier; Klara Posfay-Barbe; Stephane Grillet; Laurent Kaiser; Christian van Delden
Journal:  Antivir Ther       Date:  2012-04-27

6.  Oil-in-water emulsion adjuvant with influenza vaccine in young children.

Authors:  Timo Vesikari; Markus Knuf; Peter Wutzler; Aino Karvonen; Dorothee Kieninger-Baum; Heinz-Josef Schmitt; Frank Baehner; Astrid Borkowski; Theodore F Tsai; Ralf Clemens
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

7.  Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines.

Authors:  Sunil Kannanganat; Bill G Kapogiannis; Chris Ibegbu; Lakshmi Chennareddi; Paul Goepfert; Harriet L Robinson; Jeffrey Lennox; Rama Rao Amara
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

Review 8.  Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccines.

Authors:  Rafik Bekkat-Berkani; Riju Ray; Varsha K Jain; Vijayalakshmi Chandrasekaran; Bruce L Innis
Journal:  Expert Rev Vaccines       Date:  2015-12-05       Impact factor: 5.217

Review 9.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part I: Influenza life-cycle and currently available drugs.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-09

Review 10.  Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications.

Authors:  Erin Sparrow; Martin Friede; Mohamud Sheikh; Siranda Torvaldsen; Anthony T Newall
Journal:  Vaccine       Date:  2016-09-09       Impact factor: 3.641

View more
  9 in total

1.  Influenza-specific IgG1+ memory B-cell numbers increase upon booster vaccination in healthy adults but not in patients with predominantly antibody deficiency.

Authors:  Gemma E Hartley; Emily S J Edwards; Julian J Bosco; Samar Ojaimi; Robert G Stirling; Paul U Cameron; Katie Flanagan; Magdalena Plebanski; Philip Mark Hogarth; Robyn E O'Hehir; Menno C van Zelm
Journal:  Clin Transl Immunology       Date:  2020-10-16

Review 2.  Impact of Host Genetics and Biological Response Modifiers on Respiratory Tract Infections.

Authors:  Alicia Lacoma; Lourdes Mateo; Ignacio Blanco; Maria J Méndez; Carlos Rodrigo; Irene Latorre; Raquel Villar-Hernandez; Jose Domínguez; Cristina Prat
Journal:  Front Immunol       Date:  2019-05-07       Impact factor: 7.561

3.  Seasonal Influenza Vaccine: Uptake, Attitude, and Knowledge Among Patients Receiving Immunoglobulin Replacement Therapy.

Authors:  Fionnuala Cox; Catherine King; Anne Sloan; David J Edgar; Niall Conlon
Journal:  J Clin Immunol       Date:  2021-01-05       Impact factor: 8.317

4.  Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.

Authors:  Daniel Arroyo-Sánchez; Oscar Cabrera-Marante; Rocío Laguna-Goya; Patricia Almendro-Vázquez; Octavio Carretero; Francisco Javier Gil-Etayo; Patricia Suàrez-Fernández; Pilar Pérez-Romero; Edgard Rodríguez de Frías; Antonio Serrano; Luis M Allende; Daniel Pleguezuelo; Estela Paz-Artal
Journal:  J Clin Immunol       Date:  2021-11-17       Impact factor: 8.317

5.  Antigen-Specific CD4+ T-Cell Activation in Primary Antibody Deficiency After BNT162b2 mRNA COVID-19 Vaccination.

Authors:  Kai M T Sauerwein; Christoph B Geier; Roman F Stemberger; Hüseyin Akyaman; Peter Illes; Michael B Fischer; Martha M Eibl; Jolan E Walter; Hermann M Wolf
Journal:  Front Immunol       Date:  2022-02-14       Impact factor: 7.561

Review 6.  The pediatric common variable immunodeficiency - from genetics to therapy: a review.

Authors:  Aleksandra Szczawinska-Poplonyk; Eyal Schwartzmann; Ewelina Bukowska-Olech; Michal Biernat; Stanislaw Gattner; Tomasz Korobacz; Filip Nowicki; Monika Wiczuk-Wiczewska
Journal:  Eur J Pediatr       Date:  2021-12-23       Impact factor: 3.860

7.  Physician vaccination practices in mild to moderate inborn errors of immunity and retrospective review of vaccine completeness in IEI: results from the Canadian Immunization Research Network.

Authors:  Sneha Suresh; Joseline Zafack; Anne Pham-Huy; Beata Derfalvi; Manish Sadarangani; Athena McConnell; Bruce Tapiéro; Scott A Halperin; Gaston De Serres; Jeffrey M Pernica; Karina A Top
Journal:  Allergy Asthma Clin Immunol       Date:  2022-04-09       Impact factor: 3.406

Review 8.  Vaccination in PADs.

Authors:  Cinzia Milito; Valentina Soccodato; Giulia Collalti; Alison Lanciarotta; Ilaria Bertozzi; Marcello Rattazzi; Riccardo Scarpa; Francesco Cinetto
Journal:  Vaccines (Basel)       Date:  2021-06-09

9.  COVID-19 Vaccination Compliance and Associated Factors among Medical Students during an Early Phase of Vaccination Rollout-A Survey from Israel.

Authors:  Maayan Katz; Maya Azrad; Daniel Glikman; Avi Peretz
Journal:  Vaccines (Basel)       Date:  2021-12-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.